ResearcherKyoto UniversityNo recent work listed
Carmen Belli
Matched on ORCID iD 0000-0001-7067-7496; OpenAlex author ID A5006175430. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: none · 2015: none · 2016: 2 papers
Papers 7
- Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2932-3↗
- (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
- Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Co-author DOI 10.1016/j.ctrv.2012.09.008↗
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Co-author DOI 10.1016/j.ejca.2013.06.041↗
- A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirub… Co-author DOI 10.1007/s00280-011-1680-2↗
- Role of taxanes in pancreatic cancer. Co-author DOI 10.3748/wjg.v18.i33.4457↗
- Unity is strength: one, two, or more drugs against advanced pancreatic cancer? Co-author DOI 10.1093/annonc/mdr008↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michele Reni · 6 shared papers, 2011–2016 · strength 0.24
- Paper Neoadjuvant therapy in resectable pancreatic cancer: a critical review. DOI 10.1016/j.ctrv.2012.09.008↗
- Paper Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. DOI 10.1007/s00280-015-2932-3↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Stefano Cereda · 5 shared papers, 2011–2016 · strength 0.19
- Paper Neoadjuvant therapy in resectable pancreatic cancer: a critical review. DOI 10.1016/j.ctrv.2012.09.008↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Paper Unity is strength: one, two, or more drugs against advanced pancreatic cancer? DOI 10.1093/annonc/mdr008↗
- Claudio Doglioni · 3 shared papers, 2012–2016 · strength 0.12
- Paper Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. DOI 10.1007/s00280-015-2932-3↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Paper A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, cape… DOI 10.1007/s00280-011-1680-2↗
- Erica Dugnani · 2 shared papers, 2016 · strength 0.10
- Lorenzo Piemonti · 2 shared papers, 2016 · strength 0.10
- Gianpaolo Balzano · 2 shared papers, 2012–2016 · strength 0.07
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Paper A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, cape… DOI 10.1007/s00280-011-1680-2↗
- Eugenio Villa · 2 shared papers, 2012–2013 · strength 0.06
- Paper Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. DOI 10.1016/j.ejca.2013.06.041↗
- Paper A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, cape… DOI 10.1007/s00280-011-1680-2↗
- Luca Porcu · 1 shared paper, 2016 · strength 0.05
- Maria Giulia Cangi · 1 shared paper, 2016 · strength 0.05
- Paola Allavena · 1 shared paper, 2016 · strength 0.05
- Daniela Liberati · 1 shared paper, 2016 · strength 0.05
- Valentina Pasquale · 1 shared paper, 2016 · strength 0.05
- Massimo Falconi · 1 shared paper, 2016 · strength 0.05
- Vito Lampasona · 1 shared paper, 2016 · strength 0.05
- Erica Villa · 1 shared paper, 2011 · strength 0.04
- Andrea Mambrini · 1 shared paper, 2013 · strength 0.03
- Alessandro Passardi · 1 shared paper, 2013 · strength 0.03
- Francesca Bergamo · 1 shared paper, 2013 · strength 0.03
- Giuseppe Aprile · 1 shared paper, 2013 · strength 0.03
- Michèle Milella · 1 shared paper, 2013 · strength 0.03
- Paolo Passoni · 1 shared paper, 2012 · strength 0.03
- Michele Ghidini · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.